V3
V3V.XETRA VITA 34 AG
- Market cap
- EUR 45.1M
- P/E
- -
- P/B
- 9.56x
- ROE
- -52.3%
- Dividend yield
- 0.00%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is V3V.XETRA undervalued?
Graham numberThe Graham number of VITA 34 AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VITA 34 AG fundamental analysis
No fundamental analysis for VITA 34 AG yet.
VITA 34 AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VITA 34 AG
FamiCord AG engages in the collection, processing, storage, and distribution of cells, tissues, blood, and blood components for medical applications in Germany, Poland, Switzerland, Portugal, and internationally. The company operates through Subgroup Vita 34 And Subgroup PBKM segments. It produces and develops advanced therapies, genetic tests, and analyses for third parties. The company also engages in the development and manufacture of cell and tissue-based products and ph…
Full company profileVITA 34 AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
VITA 34 AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 16.3M | 19.2M | 20.4M | 20.2M | 20.1M | 28.4M | 68.9M | 77.1M | 82.2M | 88.2M | 86.4M |
| Gross Profit | 8.62M | 10.8M | 12.0M | 12.6M | 11.7M | 12.4M | 2.74M | 28.2M | 20.7M | 44.8M | 49.9M |
| Operating Income | 780K | 135K | 2.63M | 3.28M | 2.38M | -2.92M | -26.0M | -3.12M | -9.26M | -3.52M | -18.0K |
| EBITDA | 2.36M | 1.89M | 4.12M | 5.32M | 5.01M | 791K | -18.3M | 5.81M | -443K | 4.76M | 8.40M |
| Net Income | 408K | -322K | 828K | 1.35M | 1.45M | -3.93M | -27.4M | -1.87M | -12.1M | -6.30M | -2.64M |
| EPS | 0.13 | -0.09 | 0.20 | 0.33 | 0.35 | -0.67 | -1.73 | -0.12 | -0.70 | -0.36 | -0.15 |
| Balance Sheet | |||||||||||
| Total Assets | 43.4M | 62.0M | 59.3M | 61.1M | 58.5M | 178M | 152M | 158M | 153M | 168M | 162M |
| Total Liabilities | 19.8M | 32.3M | 29.8M | 30.8M | 28.9M | 136M | 136M | 136M | 140M | 163M | 158M |
| Shareholders' Equity | 23.6M | 29.5M | 29.4M | 30.2M | 29.6M | 43.1M | 16.5M | 23.6M | 14.1M | 7.12M | 5.05M |
| Cash & Short-term Investments | 2.81M | 4.18M | 7.09M | 9.21M | 10.5M | 35.3M | 18.2M | 17.4M | 18.5M | 11.9M | 12.4M |
| Total Debt | 3.08M | 8.70M | 7.14M | 7.29M | 5.30M | 32.4M | 28.2M | 21.6M | 18.1M | 23.5M | 23.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.29M | 1.53M | 4.60M | 6.32M | 3.98M | 2.73M | -4.49M | 9.15M | 8.66M | 3.88M | 7.08M |
| Capital Expenditure | 454K | 753K | 812K | 850K | 645K | 2.26M | 6.43M | 4.09M | 3.20M | 4.13M | 1.02M |
| Free Cash Flow | 1.83M | 777K | 3.79M | 5.47M | 3.34M | 467K | -10.9M | 5.06M | 5.46M | -249K | 6.06M |
| Ratios | |||||||||||
| ROE | 1.7% | -1.1% | 2.8% | 4.5% | 4.9% | -9.1% | -166.0% | -7.9% | -85.9% | -88.6% | -52.3% |
| ROA | 0.9% | -0.5% | 1.4% | 2.2% | 2.5% | -2.2% | -18.1% | -1.2% | -7.9% | -3.7% | -1.6% |
| Net Profit Margin | 2.5% | -1.7% | 4.1% | 6.7% | 7.2% | -13.8% | -39.7% | -2.4% | -14.8% | -7.1% | -3.1% |
| Debt to Equity | 0.13x | 0.29x | 0.24x | 0.24x | 0.18x | 0.75x | 1.71x | 0.92x | 1.28x | 3.30x | 4.56x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
VITA 34 AG dividends
- Dividend yield
- 0.00%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 5, 2019
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 2.00K | 0.00 | - |
| 2024 | EUR 2.00K | 0.00 | - |
| 2023 | EUR 7.00K | 0.00 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | EUR 656K | 0.16 | 48.6% |
| 2018 | EUR 653K | 0.16 | 78.9% |
| 2017 | EUR 474K | 0.13 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1481:1440 on Jul 14, 2017.
Who owns VITA 34 AG
- Insiders 72.00%
- Institutions 10.56%
- Public & others 17.44%
- Shares outstanding 17.4M
- Free float 6.32M
VITA 34 AG company profile
- Company name
- VITA 34 AG
- Ticker
- V3V.XETRA
- ISIN
- DE000A0BL849
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 625
- Fiscal year end
- December
- Address
- Perlickstrasse 5, Leipzig, Germany, 04103
- Phone
- 49 341 48792 5500
- Website
- famicord.com
About VITA 34 AG
FamiCord AG engages in the collection, processing, storage, and distribution of cells, tissues, blood, and blood components for medical applications in Germany, Poland, Switzerland, Portugal, and internationally. The company operates through Subgroup Vita 34 And Subgroup PBKM segments. It produces and develops advanced therapies, genetic tests, and analyses for third parties. The company also engages in the development and manufacture of cell and tissue-based products and pharmaceuticals, including the production of viral vectors or comparable products. In addition, it engages in research and development, storage, and cryopreservation of sperm and oocytes for use in reproductive medicine; and the manufacturing and distribution of medical devices. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is headquartered in Leipzig, Germany.
VITA 34 AG management
5- Mr. Jakub Julian BaranChairman of the Management Board & CEO
- Mr. Tomasz Franciszek BaranVice President of the Management Board & CMO
- Mr. Thomas PfaadtCFO & Member of Management Board
- Dr. Cornelia Wittke-KotheCCO & Member of Management Board
- Santiago LuengoManaging Director of Secuvita